Cargando…

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?

Detalles Bibliográficos
Autores principales:	Vignesh, Ramachandran, Shankar, Esaki M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651972/ https://www.ncbi.nlm.nih.gov/pubmed/28865747 http://dx.doi.org/10.1016/j.ebiom.2017.08.025

Ejemplares similares

Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents
por: Ne, Enrico, et al.
Publicado: (2022)

The enigma of forgetting
por: Wixted, John T.
Publicado: (2022)

Relevance of multiply spliced HIV-1 RNA measurement in assessing the efficacy of viral latency-reversing strategies
por: Doria, Margherita
Publicado: (2021)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

The forgetting health system
por: Coiera, Enrico
Publicado: (2017)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

The Right Ventricle—You May Forget It, But It Will Not Forget You
por: Wanner, Patrick M., et al.
Publicado: (2020)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

Valproic acid and HIV-1 latency: beyond the sound bite
por: Smith, Stephen M
Publicado: (2005)

Are We Prepared to Save the Sanctity of Science from Predatory Journals?
por: Ramachandran, Vignesh, et al.
Publicado: (2019)

The hard part we often forget: providing care to children and adolescents with advanced HIV disease
por: Frigati, Lisa Jane, et al.
Publicado: (2023)

Lest we forget the endothelial glycocalyx in sepsis
por: Burke-Gaffney, Anne, et al.
Publicado: (2012)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Commentary: Ocular lesions in leprosy – Should we forget?
por: Biswas, Jyotirmay, et al.
Publicado: (2022)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
por: Relaño-Rodríguez, Ignacio, et al.
Publicado: (2019)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
por: Ait-Ammar, Amina, et al.
Publicado: (2020)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

The Implementation of HIV Self-Testing in Resource-Limited Settings Where the HIV Disease Burden is High
por: Balakrishnan, Pachamuthu, et al.
Publicado: (2023)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

Scrub Typhus for the Neurologist: Forget Me Not
por: Kadhiravan, Tamilarasu
Publicado: (2022)

Anti-latency agents to purge HIV reservoirs
por: Moreno, Santiago
Publicado: (2012)

Inflammatory pseudotumor of urinary bladder: Beware lest we forget
por: Garg, Pankaj Kumar
Publicado: (2014)

Commentary: Do not forget to read history: You will understand and improve
por: Mestres, Carlos A.
Publicado: (2021)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

The Wages of Original Antigenic Sin
por: Morens, David M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fvob7kff3gvigc77l8i2bmhj99